Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice.

Trial Profile

Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Genital warts; Human papillomavirus infections; Penile cancer; Vulvovaginal cancer
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top